Ultime notizie per ClearPoint Neuro (NASDAQ:CLPT) Azioni

ClearPoint Neuro

ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, and ClearPoint Therapeutic Solutions.

ClearPoint Neuro Inc

UBS Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) has outperformed the market over the past 5 years by 8.85% on an annualized basis producing an average annual return of 23.15%. Currently, UBS Gr has a market capitalization of $104.45 billion. 
Buying $1000 In UBS: If an investor had bought $1000 of UBS stock 5 years ago, it would be worth $2,822.79 today based on a price of $32.58 for UBS at the time of writing.
<h3>UBS Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729262156_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,800 Today

United States Cellular Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) shares are trading higher on Friday after the company agreed to sell part of its retained spectrum licenses to Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41399651/uscellular-announces-sale-of-select-spectrum-assets-for-1-0-billion" rel="noreferrer noopener">for $1.0 billion.</a>
In particular, the company agreed to sell 663 million MHz POPs of its Cellular (850 MHz) spectrum, along with 11 million MHz POPs of AWS and 19 million MHz POPs of PCS licenses, to Verizon.
The purchase price will be paid in cash, with possible adjustments as outlined in the agreement.
Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>), as the 82% majority shareholder of US Cellular, has provided written consent approving the Verizon transaction.
Apart from this, the company has entered agreements with two other mobile network operators to sell other selected spectrum licenses.
United States Cellular plans to sell 12 million MHz POPs of its spectrum licenses in the CBRS, C-Band, and 700 MHz B/C Block bands to two other mobile network operators.
These deals are subject to regulatory approval and customary closing conditions, though the buyers and terms remain undisclosed.
After these transactions, US Cellular will retain 3.4 billion MHz POPs of low and mid-band spectrum (700 MHz, 3.45GHz, CBRS, and C-Band) and 17.2 billion MHz POPs of mmWave spectrum.
These transactions align with the company&#8217;s plan to monetize <a target="_blank" href="https://www.benzinga.com/m-a/24/05/39036795/t-mobiles-4-4b-us-cellular-and-tds-deal-promises-enhanced-rural-5g-coverage" rel="noreferrer noopener">spectrum not included in the proposed sale</a> to T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>).
Each of these transactions is contingent upon the successful closing of proposed sale to T-Mobile.
Notably, in May 2024, T-Mobile US agreed to acquire substantially all of&nbsp;the United States Cellular&nbsp;and&nbsp;TDS wireless operations, including wireless customers and stores, as well as certain specified spectrum assets for $4.4 billion in the transaction in a combination of cash and up to $2.0 billion of debt.
Verizon ended the first half of 2024 with a <a target="_blank" href="https://www.benzinga.com//node/39883078" rel="noreferrer noopener">free cash flow&nbsp;of&nbsp;$8.5 billion</a>.
Price Action: USM shares are up 11.9% at $65.71 at the last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41299017" target="_blank" rel="noreferrer noopener">Lawmakers Demand Answers From AT&amp;T, Verizon, And Lumen Over Chinese Hack</a></li>
</ul>

Equities

Mid Cap

Asset Sales

Movers

TMUS

US Cellular Sells Key Spectrum Licenses To Verizon In $1B Deal

Canaccord Genuity analyst Kingsley Crane maintains SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Buy and maintains $30 price target.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on SentinelOne, Maintains $30 Price Target

Berenberg analyst Kai Klose initiates coverage on Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) with a Buy rating and announces Price Target of $11.75.

Initiation

GMRE

Berenberg Initiates Coverage On Global Medical REIT with Buy Rating, Announces Price Target of $11.75

Former NFL running back Ricky Williams has become a powerful advocate for cannabis use in professional sports, leveraging his own experience to push for a broader acceptance of the plant's therapeutic benefits. At the recent <a href="https://www.benzinga.com/events/">Benzinga Cannabis Capital Conference</a>, Williams spoke about his journey with cannabis, highlighting how it helped him cope with the physical and mental pressures of professional football.
<h3 class="wp-block-heading">A Changing Conversation in Sports</h3>
Williams, who founded the cannabis brand Highsman in 2021, believes his personal experience has helped shift the conversation about cannabis in sports. "What I took away was that people still and actively care about media," Williams said. He emphasized that athletes are increasingly using cannabis to deal with the stress and challenges that come with high-level competition. He added, "Cannabis can be a great tool in supporting someone dealing with adversity in pursuit of something great."
With a focus on wellness, Williams explained that Highsman's message is more than just cannabis—it's about promoting personal greatness. &#8220;We're preaching that cannabis can help people achieve greatness despite the challenges,&#8221; he said. Williams hopes to continue broadening the understanding of cannabis in the athletic community and beyond.
<h3 class="wp-block-heading">Advocacy in Washington D.C.</h3>
Williams also discussed his advocacy work in Washington, D.C., where he uses his platform to push for cannabis reform. He shared that his efforts are centered around educating both himself and policymakers. &#8220;I have no idea how politicians think about or view cannabis,&#8221; he admitted, noting that his goal is to have open conversations that could lead to meaningful change. &#8220;I see it as I'm setting an example for other athletes&#8230; they can use their fame or their voice actually to make real change.&#8221;
His involvement in these discussions has been driven by his desire to make a difference, not just for athletes but for anyone who could benefit from cannabis.
<h3 class="wp-block-heading">Alternative Medicine and Preventative Health</h3>
Williams' passion for alternative medicine extends beyond cannabis. After retiring from the NFL, he studied different forms of alternative wellness, and he now advocates for a preventative approach to health. "The big thing&#8230; is that most alternative medicines focus on keeping us healthy, rather than waiting for the disease to manifest," Williams said. He believes this approach can inspire others to focus on health and well-being rather than treating disease after it occurs.
Williams' journey—from professional football to cannabis advocate and wellness entrepreneur—continues to shape the conversation about cannabis, both in sports and in broader society.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Don't miss your chance to be part of Cannabis Market Spotlight: California in Anaheim on Nov. 12. Whether you want to connect with industry leaders, explore investment opportunities, or gain the latest insights into California's cannabis market, this event has it all.&nbsp;<a href="https://cannabismarketspotlight.com/california/anaheim-november-12/" target="_blank" rel="noreferrer noopener">Secure your spot today!</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free.&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe?_gl=1&#x2A;1ajl6va&#x2A;_gcl_au&#x2A;NjI5OTQ1MTM5LjE3Mjc5MzA5MjI.&#x2A;_ga&#x2A;MTAyOTE3MTY5OC4xNzI3OTMwOTIy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcyODkxMjAzOS41LjEuMTcyODkxMjEyMC4wLjAuMA.." target="_blank" rel="noreferrer noopener">Subscribe</a>&nbsp;to our newsletter here. You can't afford to miss out if you're serious about the business.
Image: Unsplash

Cannabis

Sports

Events

Exclusives

Interview

Cannabis Can Be A 'Great Tool In Dealing With Adversity,' Says Former NFL Star Ricky Williams

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) eyes double-digit sales growth for its Singles&#8217; Day campaign in Hong Kong, thanks to a new promotion designed to waive delivery fees for Taobao users in the city.
The Chinese e-commerce juggernaut launched a 1 billion yuan ($142 million) initiative on October 1 to waive delivery charges on specific orders over 99 yuan. The update also coincides with China&#8217;s <a target="_blank" href="https://www.benzinga.com/government/24/10/41312039/whats-going-on-with-us-listed-chinese-stocks-alibaba-baidu-nio-xpeng-on-monday" rel="noreferrer noopener">recent fiscal stimulus</a> announcements to boost the economy.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/24/10/41398004/why-are-alibaba-nio-jd-com-and-other-us-listed-chinese-stocks-surging-today" rel="noreferrer noopener">Why Are Alibaba, Nio, JD.Com And Other US-Listed Chinese Stocks Surging Today?</a>
Taobao, Alibaba&#8217;s leading online shopping platform in mainland China, has already seen significant year-on-year growth in both gross merchandise value (GMV) and order volume in Hong Kong, the South China Morning Post <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3282786/alibaba-sees-double-digit-sales-growth-singles-day-hong-kong" rel="noreferrer noopener">reports</a>.
David Ye Jianqiu, general manager of Tmall Taobao World, noted that user feedback on the free shipping initiative has been overwhelmingly positive. He expressed confidence that Taobao will achieve double-digit year-on-year GMV growth during this year&#8217;s Singles&#8217; Day event in Hong Kong.
The company focuses on markets outside mainland China, as the intense competition in the domestic market prompted a price war.
Taobao and Tmall remained invested in multiple initiatives to boost value. <a target="_blank" href="https://www.benzinga.com/news/24/07/40007141/alibaba-stock-soars-as-new-service-fees-boost-revenue" rel="noreferrer noopener">Beginning in September</a>, Alibaba shared plans to introduce a 0.6% software service fee on confirmed transactions for vendors using its Tmall and Taobao platforms to boost Alibaba&#8217;s core merchant revenue significantly.
Jefferies Financial Group analysts highlighted that Alibaba currently generates most of its Taobao and Tmall revenue from customer management fees, which merchants pay to advertise and customize their product offerings.
Taobao and Tmall Group (TTG) established a new <a target="_blank" href="https://www.benzinga.com/news/24/09/40708358/alibabas-taobao-and-tmall-launch-new-tech-venture-eyeing-global-market-growth" rel="noreferrer noopener">&#8220;digital technology&#8221; company</a> with a registered capital of 10 million yuan ($1.4 million). The company is focused on importing and exporting goods, selling food, daily groceries, outdoor products, and household appliances, and offering technology services like software development and tech transfer.
Alibaba&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40390854/alibaba-q1-earnings-revenue-miss-amid-price-war-profit-beat-international-commerce-and-cloud-segmen" rel="noreferrer noopener">fiscal first-quarter</a> topline grew by 4% to $33.47 billion, missing the consensus estimate of $34.81 billion. Taobao and Tmall Group revenue declined by 1% to $15.60 billion.
Price Action: BABA stock is up 2.18% at $102.26 at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41399541/apple-iphone-16-sees-20-sales-surge-in-china-but-ai-absence-prompts-early-price-cuts" target="_blank" rel="noreferrer noopener">Apple iPhone 16 Sees 20% Sales Surge in China, But AI Absence Prompts Early Price Cuts</a></li>
</ul>
Photo by BEAUTY STUDIO via Shutterstock

Emerging Markets

Media

BABA

Alibaba Eyes Double-Digit Growth for Singles' Day in Hong Kong, Waives Delivery Fees

Piper Sandler analyst Andrew Liesch maintains Great Southern Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSBC#NASDAQ">GSBC</a>) with a Neutral and lowers the price target from $64 to $62.

GSBC

Piper Sandler Maintains Neutral on Great Southern Bancorp, Lowers Price Target to $62

Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and maintains $21 price target.

DCTH

Canaccord Genuity Maintains Buy on Delcath Systems, Maintains $21 Price Target

Piper Sandler analyst Frank Schiraldi maintains Cass Information Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASS#NASDAQ">CASS</a>) with a Overweight and raises the price target from $44 to $45.

CASS

Piper Sandler Maintains Overweight on Cass Information Sys, Raises Price Target to $45

<a href="https://www.atlantafed.org/news/press-room/media-advisories/2024/10/18/bostic-lecture-millsaps-college-mississippi" title="https://www.atlantafed.org/news/press-room/media-advisories/2024/10/18/bostic-lecture-millsaps-college-mississippi">https://www.atlantafed.org/news/press-room/media-advisories/2024/10/18/bostic-lecture-millsaps-college-mississippi</a>

Federal Reserve

Fed's Bostic Says May See A Lull In Investment Activity, Household Spending Amid Election Uncertainty

BlackRock&#8217;s iShares Bitcoin Trust&nbsp;(NASDAQ:&nbsp;IBIT) ETF has attracted over $1 billion in inflows this week alone, which has helped propel the apex crypto to a <a href="https://www.tradingview.com/news/benzinga:01854bfbd094b:0-bitcoin-takes-aim-at-all-time-highs-what-does-it-mean-for-altcoins/">10% seven-day gain</a>.
What Happened: According to <a href="https://sosovalue.xyz/assets/etf/us-btc-spot">data</a> from SoSo Value, <a href="https://www.benzinga.com/topic/bitcoin-etf">spot bitcoin ETFs</a> in the U.S. garnered $470 million on Thursday alone. BlackRock&#8217;s IBIT was the frontrunner, pulling in $309 million, contributing to a total of $1.07 billion for the week.
Overall, spot bitcoin ETFs have experienced significant inflows, with 12 funds amassing over $1.85 billion this week. Ark and 21Shares&#8217; (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>) saw over $100 million in inflows. Grayscale&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#OTC">GBTC</a>) recorded $45.70 million, while Fidelity&#8217;s (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>) had $11.69 million. 
According to crypto analyst Rachael Lucas, <a href="https://www.theblock.co/post/321888/blackrock-spot-bitcoin-etf-draws-in-1-billion-so-far-this-week?utm_source=rss&amp;utm_medium=rss">per</a> The Block, this trend is due to favorable macroeconomic conditions. When central banks reduce interest rates, investors explore alternative assets.
Thursday&#8217;s trading volume for bitcoin ETFs was approximately $1.47 billion, slightly lower than the previous day. Since January, cumulative net inflows have reached $20.66 billion, a milestone <a href="https://x.com/EricBalchunas/status/1846885254356770924">described</a> by Bloomberg&#8217;s Eric Balchunas as &#8220;the most important metric in ETF world.&#8221;
Spot Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETFs also reported positive flows, with $48.41 million on Thursday. Fidelity&#8217;s (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FETH#BATS">FETH</a>) led with $31.12 million, followed by BlackRock&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>) with $23.56 million. Despite these gains, Grayscale&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ETHE#OTC">ETHE</a>) experienced $15.74 million in outflows.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41391989/exclusive-robinhoods-bitstamp-deal-will-drive-growth-exec-says-what-was-good-for-stocks-we">EXCLUSIVE: Robinhood&#8217;s Bitstamp Deal Will Drive Growth, Exec Says: &#8216;What Was Good For Stocks &#8230; We Brought Into Crypto&#8217;</a>
Why It Matters: The surge in inflows Bitcoin ETFs comes as the cryptocurrency industry continues to grow according to important metrics. 
According to a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41386011/bitcoin-etfs-ethereum-staking-stablecoins-power-crypto-growth-in-2024-coinbase-report">recent report</a> by Coinbase and Glassnode, the crypto market is maturing, with successful spot ETFs and increased trading volumes cited as key growth drivers. Venture capital firm a16z found in a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41383239/crypto-hits-unprecedented-growth-7-major-findings-from-2024-report">separate report</a> that monthly active addresses are at all-time highs, up thrice from levels at the end of 2023.
The Securities and Exchange Commission had approved Bitcoin ETFs in January this year, following a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41386377/arrest-made-in-sec-x-account-hack-prior-to-bitcoin-etf-approval-fbi-says-phone-used-to-man">controversial incident</a> involving a hack of the SEC&#8217;s account.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41389551/musk-cuban-or-saylor-whos-the-biggest-crypto-influencer-benzinga-readers-have-an-overwhelm">Musk, Cuban, Or Saylor: Who&#8217;s The Biggest Crypto Influencer? Benzinga Readers Have An Overwhelming Favorite</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

ETHA

ETHE

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

Fidelity Ethereum Fund Fidelity Ethereum Fund

FETH

GBTC

IBIT

BlackRock's Bitcoin ETF Gobbles Up $1B This Week, Fidelity Leads Among Ethereum ETFs With $31M

Piper Sandler analyst Scott Siefers maintains Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Underweight and raises the price target from $14 to $15.

HBAN

Piper Sandler Maintains Underweight on Huntington Bancshares, Raises Price Target to $15

Canaccord Genuity analyst George Gianarikas maintains ASP Isotopes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) with a Buy and maintains $4.5 price target.

ASPI

Canaccord Genuity Maintains Buy on ASP Isotopes, Maintains $4.5 Price Target

In the current market session, PNC Finl Servs Gr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) stock price is at $188.60, after a 0.11% decrease. However, over the past month, the company's stock spiked by 1.20%, and in the past year, by 71.91%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729261810_0.png" alt="Past Year Chart" />

<h3>Evaluating PNC Finl Servs Gr P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 13.44 in the Banks industry, PNC Finl Servs Gr Inc. has a higher P/E ratio of 15.96. Shareholders might be inclined to think that PNC Finl Servs Gr Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729261810_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for PNC Finl Servs Gr

Canaccord Genuity analyst Kingsley Crane maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Hold and lowers the price target from $90 to $82.

OKTA

Canaccord Genuity Maintains Hold on Okta, Lowers Price Target to $82

Piper Sandler analyst Stephen Scouten maintains Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) with a Overweight and raises the price target from $30 to $31.

HOMB

Piper Sandler Maintains Overweight on Home BancShares, Raises Price Target to $31

Bernstein analyst Laurent Yoon maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Market Perform and raises the price target from $625 to $780.

NFLX

Bernstein Maintains Market Perform on Netflix, Raises Price Target to $780

Canaccord Genuity analyst Maria Ripps maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Hold and raises the price target from $750 to $760.

Canaccord Genuity Maintains Hold on Netflix, Raises Price Target to $760

Piper Sandler analyst Nathan Race maintains Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) with a Overweight and raises the price target from $22.5 to $23.

OSBC

Piper Sandler Maintains Overweight on Old Second Bancorp, Raises Price Target to $23

U.S. stocks traded mixed this morning, with the Dow Jones falling over 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.35% to 43,086.52 while the NASDAQ rose 0.73% to 18,507.31. The S&amp;P 500 also rose, gaining, 0.26% to 5,856.65.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Communication services shares jumped by 1.4% on Friday.
In trading on Friday, energy shares fell by 0.6%.
Top Headline
Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected third-quarter financial results, posting revenue of $9.825 billion, up 15% year-over-year, versus market estimates of $9.769 billion.
The company ended the third quarter with 282.72 million global paid subscribers, up 14.4% year-over-year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Catheter Precision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NASDAQ">VTAK</a>) shares shot up 249% to $1.54.</li>
<li>Shares of Bright Minds Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) got a boost, surging 133% to $50.66. The company announced a $35 million non-brokered private placement.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares were also up, gaining 96% to $15.55 after the company announced it filed a form RW and will not pursue a public offering at this time.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares dropped 38% to $0.4301.</li>
<li>Shares of Orgenesis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) were down 34% to $2.1100.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) was down, falling 31% to $1.5950.</li>
</ul>
Commodities In commodity news, oil traded down 1.5% to $69.59 while gold traded up 0.8% at $2,730.00.
Silver traded up 2.9% to $32.690 on Friday, while copper rose 1.3% to $4.3815.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.1%, Germany's DAX rose 0.2% and France's CAC 40 climbed 0.2%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 fell 0.8%.
Construction output in the Eurozone fell by 2.5% year-over-year in August compared to a revised 2.3% decline in the previous month. The current account surplus in the Eurozone increased to €35.2 billion in August from €26.8 billion in the year-ago period.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index climbing 3.61%, China's Shanghai Composite Index gaining 2.91% and India's BSE Sensex gaining 0.27%.
Economics
<ul>
<li>U.S. housing starts fell by 0.5% from the previous month to an annualized rate of 1.354 million units in September.</li>
<li>Building permits declined by 2.9% to an annual rate of 1.428 million in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Eurozone

Commodities

DRUG

NKGN

NUZE

ORGS

SOBR

VTAK

Dow Falls Over 100 Points; Netflix Posts Upbeat Results

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on ClearPoint Neuro (CLPT – Research Report). The company's sha...

Lake Street Remains a Buy on ClearPoint Neuro (CLPT)

ClearPoint Neuro GAAP EPS of -$0.16 beats by $0.02, revenue of $7.9M beats by $0.57M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ClearPoint Neuro (NASDAQ:<a href="https://investorplace.com/stock-quotes/clpt-stock-quote/">CLPT</a>) just reported results for the second quarter of 2024.<ul><li>ClearPoint Neuro reported earnings per share of -16 cents. This was above the analyst estimate for EPS of -20 cents.</li><li>The company reported revenue of $7.86 million.</li><li>This was 7.20% better than the analyst estimate for revenue of $7.33 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/clpt-stock-earnings-clearpoint-neuro-for-q2-of-2024/">CLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q2 2024

ClearPoint Neuro, Inc. (CLPT) Q2 2024 Earnings Call Transcript

ClearPoint Neuro: My Favorite Growth Stock

ClearPoint: Growth Tailwinds Are Only Just Beginning To Emerge (Rating Downgrade)

ClearPoint Neuro fully repays $10M converted note

ClearPoint Neuro (CLPT) has provided an announcement. ClearPoint Neuro, Inc. has proactively prepaid certain convertible notes, a move that reflect...

ClearPoint Neuro Preempts Convertible Note Obligations

Lake Street analyst Frank Takkinen reiterated a Buy rating on ClearPoint Neuro (CLPT – Research Report) today. The company's shares closed yesterda...

Lake Street Sticks to Their Buy Rating for ClearPoint Neuro (CLPT)

Lake Street Reaffirms Their Buy Rating on ClearPoint Neuro (CLPT)

CLPT

Press Releases

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)

Health Care

General

ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore

Earnings

ClearPoint Neuro Reports First Quarter 2024 Results

ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System

Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

ClearPoint Neuro Reports Second Quarter 2024 Results

ClearPoint Neuro Announces Early Repayment of $10 Million Note

ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

AngioDynamics

Alphatec Holdings

Axogen

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

CeriBell

Delcath Systems

Electromed

Paragon 28

Inogen

iRadimed

Pulmonx

NeuroPace

Nevro

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Hldgs

Orthofix Medical

Senseonics Holdings

Sight Sciences

SI-BONE

Surmodics

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Tech

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts

Varex Imaging

ZimVie

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Comments

ClearPoint Neuro

Notizie

Ultime notizie per ClearPoint Neuro (NASDAQ:CLPT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO